Omeros Corporation MASP-2 Inhibitors Patent EP4069238A1

The European Patent Office published patent application EP4069238A1 for Omeros Corporation, covering MASP-2 inhibitor compounds and methods of use for treating various conditions. The application includes claims to chemical compositions falling under IPC classifications for pyrimidine compounds (C07D401/12, C07D401/14, C07D403/12) and fused heterocyclic systems (C07D471/04, C07D471/10, C07D493/04, C07D495/04), along with therapeutic use claims across multiple A61P categories including metabolic disorders (A61P3/00), coagulation disorders (A61P7/00, A61P7/02), cardiovascular conditions (A61P9/00), respiratory diseases (A61P11/00), kidney/urinary tract disorders (A61P13/00), eye conditions (A61P27/02), and inflammatory/analgesic applications (A61P29/00).

Pharmaceutical companies developing complement system inhibitors should review this publication for freedom-to-operate implications in European markets. Researchers and biotech firms working on MASP-2 targeting programs should consider this landscape data for patent strategy. The patent designation covers all 31 European Patent Convention member states and extension countries including Albania, Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Monaco, North Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, and Turkey.